Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) — confirmed by tissue sample, cell sample, or clinical assessment — at a stage classified as BCLC A or B that falls outside the Milan criteria (a standard used to assess liver cancer spread)
• People whose liver is functioning at a level classified as Child-Pugh Grade A or B (a measure of liver health)
• People who have not previously received first-line liver cancer drug treatments such as Sorafenib or Lenvatinib
• People who have at least one measurable tumour (at least 10mm on a CT scan) that has not been treated with radiation, freezing, or other local procedures
• People with a physical performance score of 0–2 on the ECOG scale, meaning they are able to carry out at least some daily activities (confirm with trial site)
• People whose life expectancy is estimated to be at least 12 weeks
• People whose blood counts, kidney function, and liver function test results fall within the ranges required by the trial (confirm with trial site for specific values)
• People with hepatitis B or C who are already taking antiviral medications and have not used interferon treatment
• Women of childbearing age who have a negative pregnancy test within 7 days before joining, are not breastfeeding, and agree to use contraception during the trial and for 6 months after it ends; men who agree to use contraception during the trial and for 6 months after it ends
• People who have voluntarily agreed to take part and have signed an informed consent form

Who may not be able to join:

• People who have previously received immunotherapy drugs or interferon treatment
• People who have a known allergy to any of the drugs used in this trial
• Women who are pregnant or currently breastfeeding
• People who have previously received immunotherapy drugs that target the PD-1 or PD-L1 pathways (a specific type of cancer immunotherapy)
• People with serious or uncontrolled heart conditions, including significant heart failure, unstable chest pain, a heart attack within the past year, certain abnormal heart rhythms requiring treatment, or high blood pressure that is not well controlled by medication and is considered high risk by a doctor
• People who have had another type of cancer in the past or currently have a second cancer — except for certain cured cancers such as a specific type of skin cancer (basal cell carcinoma), early-stage cervical cancer, or papillary thyroid cancer
• People who have a serious active infection before starting treatment, or who have shown signs of infection or needed antibiotic treatment (other than preventive antibiotics) within 2 weeks before the first dose
• People with a history of immune system deficiency, HIV, certain autoimmune or inflammatory conditions, a history of organ or bone marrow transplant, or who are currently taking steroids or other immune-suppressing medications (some exceptions may apply — confirm with trial site)
• People with serious blood clotting problems or a significant history of bleeding (such as vomiting blood or bloody stools regularly in the past 3 months)
• People with a history of substance misuse that cannot be stopped, significant mental health conditions, cancer that has spread to the brain, or a condition called hepatic encephalopathy (a complication of liver disease affecting the brain)
• People whom the trial investigators believe may have other medical, personal, or social circumstances that could make participation unsafe or affect the reliability of trial results

Important: Always verify eligibility with the trial site directly before applying.